Published in PLoS One on July 08, 2014
Fibroblast growth factor signaling in skeletal development and disease. Genes Dev (2015) 1.04
A Genetic-Pathophysiological Framework for Craniosynostosis. Am J Hum Genet (2015) 1.02
Effects of Citalopram on Sutural and Calvarial Cell Processes. PLoS One (2015) 0.76
Modeling craniofacial and skeletal congenital birth defects to advance therapies. Hum Mol Genet (2016) 0.75
ESRP1 and ESRP2 are epithelial cell-type-specific regulators of FGFR2 splicing. Mol Cell (2009) 5.03
Apert syndrome results from localized mutations of FGFR2 and is allelic with Crouzon syndrome. Nat Genet (1995) 4.01
Mutations in the fibroblast growth factor receptor 2 gene cause Crouzon syndrome. Nat Genet (1994) 2.83
Identical mutations in the FGFR2 gene cause both Pfeiffer and Crouzon syndrome phenotypes. Nat Genet (1995) 2.49
RNA interference and inhibition of MEK-ERK signaling prevent abnormal skeletal phenotypes in a mouse model of craniosynostosis. Nat Genet (2007) 2.22
Integration of FGF and TWIST in calvarial bone and suture development. Development (2000) 2.15
Loss of fibroblast growth factor receptor 2 ligand-binding specificity in Apert syndrome. Proc Natl Acad Sci U S A (2000) 2.13
Jackson-Weiss and Crouzon syndromes are allelic with mutations in fibroblast growth factor receptor 2. Nat Genet (1994) 2.06
Wnt/β-catenin signaling and AXIN1 regulate apoptosis triggered by inhibition of the mutant kinase BRAFV600E in human melanoma. Sci Signal (2012) 1.95
Abnormalities in cartilage and bone development in the Apert syndrome FGFR2(+/S252W) mouse. Development (2005) 1.93
A modified technique for organ culture in vitro. Exp Cell Res (1954) 1.85
Craniosynostosis. Eur J Hum Genet (2011) 1.84
A splicing switch and gain-of-function mutation in FgfR2-IIIc hemizygotes causes Apert/Pfeiffer-syndrome-like phenotypes. Proc Natl Acad Sci U S A (2001) 1.56
A Ser252Trp [corrected] substitution in mouse fibroblast growth factor receptor 2 (Fgfr2) results in craniosynostosis. Bone (2003) 1.50
De novo alu-element insertions in FGFR2 identify a distinct pathological basis for Apert syndrome. Am J Hum Genet (1999) 1.50
Fibroblast growth factor receptor 2 mutations in Beare-Stevenson cutis gyrata syndrome. Nat Genet (1996) 1.49
Nanogel antigenic protein-delivery system for adjuvant-free intranasal vaccines. Nat Mater (2010) 1.45
Signaling through fibroblast growth factor receptor 2b plays a key role in the development of the exocrine pancreas. Proc Natl Acad Sci U S A (1999) 1.38
Increased calvaria cell differentiation and bone matrix formation induced by fibroblast growth factor receptor 2 mutations in Apert syndrome. J Clin Invest (1998) 1.30
Early onset of craniosynostosis in an Apert mouse model reveals critical features of this pathology. Dev Biol (2009) 1.24
Fibroblast growth factor receptor 2 promotes osteogenic differentiation in mesenchymal cells via ERK1/2 and protein kinase C signaling. J Biol Chem (2008) 1.18
Fgfr mRNA isoforms in craniofacial bone development. Bone (2003) 1.08
A soluble form of fibroblast growth factor receptor 2 (FGFR2) with S252W mutation acts as an efficient inhibitor for the enhanced osteoblastic differentiation caused by FGFR2 activation in Apert syndrome. J Biol Chem (2004) 1.07
Apoptosis in murine calvarial bone and suture development. Eur J Oral Sci (1999) 1.06
HER2-specific T-cell immune responses in patients vaccinated with truncated HER2 protein complexed with nanogels of cholesteryl pullulan. Clin Cancer Res (2006) 1.05
Decreased proliferation and altered differentiation in osteoblasts from genetically and clinically distinct craniosynostotic disorders. Am J Pathol (1999) 1.02
Humoral immune responses in patients vaccinated with 1-146 HER2 protein complexed with cholesteryl pullulan nanogel. Cancer Sci (2007) 0.99
Nanogel engineering for new nanobiomaterials: from chaperoning engineering to biomedical applications. Chem Rec (2010) 0.97
Osteoblastic bone formation is induced by using nanogel-crosslinking hydrogel as novel scaffold for bone growth factor. J Cell Physiol (2009) 0.93
Therapeutic efficacy of soluble receptor activator of nuclear factor-kappa B-Fc delivered by nonviral gene transfer in a mouse model of osteolytic osteosarcoma. Mol Cancer Ther (2008) 0.89
The study of abnormal bone development in the Apert syndrome Fgfr2+/S252W mouse using a 3D hydrogel culture model. Bone (2008) 0.87
Convergent signalling through Fgfr2 regulates divergent craniofacial morphogenesis. J Exp Zool B Mol Dev Evol (2009) 0.86
Dual crosslinked hydrogel nanoparticles by nanogel bottom-up method for sustained-release delivery. Colloids Surf B Biointerfaces (2011) 0.84
Nanogel DDS enables sustained release of IL-12 for tumor immunotherapy. Biochem Biophys Res Commun (2007) 0.84
Absence of endochondral ossification and craniosynostosis in posterior frontal cranial sutures of Axin2(-/-) mice. PLoS One (2013) 0.82
Cholesteryl group- and acryloyl group-bearing pullulan nanogel to deliver BMP2 and FGF18 for bone tissue engineering. Biomaterials (2012) 0.82
Medical treatment of craniosynostosis: recombinant Noggin inhibits coronal suture closure in the rat craniosynostosis model. Orthod Craniofac Res (2009) 0.80
Apoptosis in a rodent model of cranial suture fusion: in situ imaging and gene expression analysis. Plast Reconstr Surg (2004) 0.80
Soluble form of FGFR2 with S252W partially prevents craniosynostosis of the apert mouse model. Dev Dyn (2013) 0.79
The use of cationic nanogels to deliver proteins to myeloma cells and primary T lymphocytes that poorly express heparan sulfate. Biomaterials (2011) 0.78
Apert syndrome mutant FGFR2 and its soluble form reciprocally alter osteogenesis of primary calvarial osteoblasts. J Cell Physiol (2012) 0.77
Correction of a deformed thumb by distraction of the phalanx. Scand J Plast Reconstr Surg Hand Surg (2002) 0.77